Amphastar Pharmaceuticals Director Michael A. Zasloff Purchases 3,500 Shares (AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Michael A. Zasloff bought 3,500 shares of Amphastar Pharmaceuticals stock on the open market in a transaction dated Tuesday, August 19th. The stock was purchased at an average cost of $10.00 per share, with a total value of $35,000.00. Following the completion of the purchase, the director now directly owns 17,639 shares in the company, valued at approximately $176,390. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 10.07 on Friday. Amphastar Pharmaceuticals has a 1-year low of $6.67 and a 1-year high of $11.07. The stock has a 50-day moving average of $9.43 and a 200-day moving average of $9.47. The company’s market cap is $437.1 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.13. On average, analysts predict that Amphastar Pharmaceuticals will post $-0.17 earnings per share for the current fiscal year.
A number of research firms have recently commented on AMPH. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.
Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.